Researchers unravel pathways of potent antibodies that fight HIV infection

March 03, 2016

DURHAM, N.C. - One of the most crucial and elusive goals of an effective HIV vaccine is to stimulate antibodies that can attack the virus even as it relentlessly mutates.

Now a research team, led by investigators at the Duke Human Vaccine Institute and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID), has tracked rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed.

The details form a blueprint that will help guide researchers as they try to build an experimental vaccine that recreates the pathway that gives rise to the important broadly neutralizing antibodies.

The findings are reported online March 3, 2016 in the journal Cell.

"We have followed a less potent neutralizing lineage in this particular individual before, but now we have found a far more potent antibody and have been able to study its development over six years," said first author Mattia Bonsignori, M.D., of the Duke Human Vaccine Institute. "With sequential structures, we can see the changes that occurred in both antibody and virus."

The work was aided by the identification six years ago of a person in Africa whose HIV was diagnosed within weeks of infection and who provided blood samples to researchers periodically from the time of diagnosis, allowing researchers to examine in real time the co-evolution of the virus and the body's immune response.

Using high-resolution electron microscopes and building structural models, the scientists were able to see the antibodies binding to the HIV envelope and the complicated structural changes that occurred in the antibody and the virus.

"We could visualize this complex dance between the virus and the antibody and understand exactly how the virus was teaching the antibody to be a broadly neutralizing antibody," said Peter D. Kwong, Ph.D., chief of the Structural Biology Section at the NIAID Vaccine Research Center.

Kwong said understanding that interaction has been an important piece of the puzzle for vaccine development, because HIV mutates so rapidly. Broadly neutralizing HIV antibodies have been isolated from chronically infected people, giving HIV vaccine developers hope that they could stimulate production of such antibodies in healthy people as protection against the virus.

"Now we've been able to go back and see what happened," said senior author Barton F. Haynes, director of the Duke Human Vaccine Institute. "We hope we can recreate this pathway but because it is so tortuous, it will be difficult."

Haynes said the research team's insights would be tested in animal models. He said a second key to creating an effective vaccine is understanding how the body's immune system often thwarts development of broadly neutralizing antibodies. Work to solve that is ongoing.
-end-
In addition to Haynes and Bonsignori, study authors from Duke include Feng Gao, Kevin Wiehe, S. Munir Alam, Todd Bradley, Morgan Gladden, Kwan-Ki Hwang, Sheelah Iyengar, Amit Kumar, Xiaozhi Lu, Kan Luo, Michael C. Mangiapani, Robert J. Parks, Hongshuo Song, David C. Montefiori, Michael A. Moody, Garnett Kelsoe, and Hua-Xin Liao.

Dr. Kwong was joined by authors from the NIAID Vaccine Research Center, part of the National Institutes of Health, including co-first authors Tongqing Zhou and Lei Chen, and M. Gordon Joyce, Gwo-Yu Chuang, Priyamvada Acharya, Robert T. Bailer, Allen Cao, Aliaksandr Druz, Ivelin S. Georgiev, Young D. Kwon, Mark K. Louder, Baoshan Zhang, Anqi Zheng, Brenna J. Hill, Rui Kong, Cinque Soto, Daniel C. Douek, and John R. Mascola.

Additional authors include co-first author Zizhang Sheng, Chaim A. Schramm and Lawrence Shapiro from Columbia University; Gabriel Ozorowski and Andrew B. Ward from The Scripps Research Institute; James C. Mullikin from NIH Intramural Sequencing Center; George M. Shaw and Beatrice H. Hahn from the University of Pennsylvania; Peter T. Hraber and Bette T. Korber from Los Alamos National Laboratory; Scott D. Boyd and Andrew Z. Fire of Stanford Univesity; and Thomas B. Kepler of Boston University.

The research received support from NIAID through the Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (UM1 AI100645); the Scripps CHAVI-ID (UM1 AI1006630); and the Scripps HIVRAD (P01-AI1047220). The International AIDS Vaccine Initiative also provided funds for the study.

Duke University Medical Center

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.